These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19615485)

  • 1. [Trastuzumab's association with cerebral metastases and meningeal carcinomatosis in a patient with HER2-positive breast cancer].
    Ayuga Loro F; Jiménez Caballero PE; Martínez Barbeito MB; Cruz Mora MA
    Med Clin (Barc); 2009 Jul; 133(7):279-80. PubMed ID: 19615485
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
    Martens J; Venuturumilli P; Corbets L; Bestul D
    Acta Oncol; 2013 Jan; 52(1):175-8. PubMed ID: 22655969
    [No Abstract]   [Full Text] [Related]  

  • 3. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid cytology diagnosis of HER2-positive leptomeningeal carcinomatosis from HER2-positive metastatic gastric cancer: case report.
    Cavanna L; Rocchi A; Gorgni S; Ambroggi M; Foroni RP; Ubbiali A; Civardi G
    J Clin Oncol; 2011 May; 29(13):e367-8. PubMed ID: 21300922
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
    Niwińska A; Tacikowska M; Murawska M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
    Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
    Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
    Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
    J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report.
    Church DN; Bahl A; Jones A; Price CG
    J Neurooncol; 2006 Sep; 79(3):289-92. PubMed ID: 16821088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain metastases in patients receiving trastuzumab for breast cancer.
    Salmaggi A; Silvani A; Boiardi A
    Neurol Sci; 2007 Mar; 28(1):1. PubMed ID: 17385088
    [No Abstract]   [Full Text] [Related]  

  • 11. [A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy].
    Takahashi H; Fujii T; Inoue Y; Katsura M; Yokoyama G; Matsubayashi Namoto R; Nakayama Y; Momosaki S; Ariyama H; Takenaka M; Otsuka H; Iwakuma N; Toh U; Shirouzu K
    Gan To Kagaku Ryoho; 2010 Aug; 37(8):1607-9. PubMed ID: 20716898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
    Yau T; Swanton C; Chua S; Sue A; Walsh G; Rostom A; Johnston SR; O'Brien ME; Smith IE
    Acta Oncol; 2006; 45(2):196-201. PubMed ID: 16546866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.
    Āboliņš A; Vanags A; Trofimovičs G; Miklaševičs E; Gardovskis J; Štrumfa I
    Pol J Pathol; 2011; 62(1):65-8. PubMed ID: 21574108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
    Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
    Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Brain metastases in breast cancer: a special disease course for HER2 positive tumors].
    Hurkens KP; Hupperets PS; Creemers GJ; Erdkamp FL; van de Vijver KK; Tjan-Heijnen VC
    Ned Tijdschr Geneeskd; 2008 Dec; 152(50):2701-6. PubMed ID: 19192581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain metastases in patients receiving trastuzumab for breast cancer.
    Errante D; Bernardi D; Bianco A; Salvagno L
    Neurol Sci; 2007 Mar; 28(1):52-3. PubMed ID: 17385098
    [No Abstract]   [Full Text] [Related]  

  • 17. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
    Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
    Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal trastuzumab: dose matters.
    Hofer S; Mengele K; Stemmler HJ; Schmitt M; Pestalozzi B
    Acta Oncol; 2012 Sep; 51(7):955-6. PubMed ID: 22524214
    [No Abstract]   [Full Text] [Related]  

  • 19. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.
    Mego M; Sycova-Mila Z; Obertova J; Rajec J; Liskova S; Palacka P; Porsok S; Mardiak J
    Breast; 2011 Oct; 20(5):478-80. PubMed ID: 21700455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.